Outcomes of additional chemotherapy for esophageal squamous cell carcinoma following non-curative endoscopic submucosal dissection
International Journal of Clinical Oncology · 2025
DOI: 10.1007/s10147-025-02893-0 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Clinical Oncology, 2025. Verfasst von Yujiro Adachi und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology and Hepatology, The University of Osaka Graduate School of Medicine, 2-2 Yamadaoka, Suita, Osaka, 565-0871, Japan. Hauptthemen laut MEDLINE: Esophageal Squamous Cell Carcinoma, Endoscopic Mucosal Resection, Esophageal Neoplasms. Die Arbeit nennt 35 Literaturangaben.
Themen: Onkologische Pflege
Abstract (Originalsprache)
BACKGROUND: Pathological T1a-muscularis mucosa with lymphovascular invasion and T1b-submucosa are high-risk factors for lymph node metastasis in esophageal squamous cell carcinoma (ESCC). Esophagectomy and chemoradiotherapy are recommended following endoscopic submucosal dissection (ESD) but can lead to complications. Here, we evaluated the efficacy and safety of chemotherapy following ESD. METHODS: This prospective and retrospective study included patients with pathological T1a-muscularis mucosa with lymphovascular invasion or T1b-submucosa who underwent esophageal ESD between June 2006 and August 2023, followed by chemotherapy or chemoradiotherapy. The overall survival, cause-specific survival, recurrence-free survival, hospitalization period, and the occurrence of grade ≥ 3 adverse events were compared between the chemotherapy and chemoradiotherapy groups. RESULTS: The patient and tumor characteristics and pathological findings did not significantly differ between the chemotherapy (n = 16) and chemoradiotherapy (n = 15) groups. The 5-year overall and recurrence-free survival rates were significantly higher in the chemotherapy group than in the chemoradiotherapy group (100.0% vs. 77.8%, P < 0.001 and 92.3% vs. 84.9%, P = 0.007, respectively; log-rank test). The 5-year cause-specific survival rate did not significantly differ between groups (100.0% vs. 83.3%, P = 0.14, log-rank test). The hospitalization period was significantly shorter in the chemotherapy group than in the chemoradiotherapy group (34 vs. 48 days, P < 0.001). Grade ≥ 3 adverse events occurred in 4 (25.0%) and 11 (73.3%) patients in the chemotherapy and chemoradiotherapy groups, respectively. CONCLUSIONS: Chemotherapy is a safe and effective additional treatment for ESCC (pathological T1a-muscularis mucosa with lymphovascular invasion or T1b-submucosa) after ESD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Gastroenterology and Hepatology, The University of Osaka Graduate School of Medicine, 2-2 Yamadaoka, Suita, Osaka, 565-0871, Japan.
- Department of Gastroenterology and Hepatology, The University of Osaka Graduate School of Medicine, 2-2 Yamadaoka, Suita, Osaka, 565-0871, Japan. y.hayashi@gh.med.osaka-u.ac.jp.
- Department of Gastroenterology and Hepatology, Ikeda Municipal Hospital, Osaka, Japan.
- Kansai Rosai Hospital, Hyogo, Japan.
Zitieren
APA
Adachi, Y., Hayashi, Y., Yoneda, S., Tajiri, A., Fukuda, H., Kimura, E., Nakagawa, K., Saiki, H., Uema, R., Yoshihara, T., Tsujii, Y., & Takehara, T. (2025). Outcomes of additional chemotherapy for esophageal squamous cell carcinoma following non-curative endoscopic submucosal dissection. International Journal of Clinical Oncology. https://doi.org/10.1007/s10147-025-02893-0
Vancouver
Adachi Y, Hayashi Y, Yoneda S, Tajiri A, Fukuda H, Kimura E, et al. Outcomes of additional chemotherapy for esophageal squamous cell carcinoma following non-curative endoscopic submucosal dissection. International Journal of Clinical Oncology. 2025. doi:10.1007/s10147-025-02893-0
BibTeX
@article{Adachi2025,
author = {Adachi, Yujiro and Hayashi, Yoshito and Yoneda, Shinji and Tajiri, Ayaka and Fukuda, Hiromu and Kimura, Eiji and Nakagawa, Kentaro and Saiki, Hirotsugu and Uema, Ryotaro and Yoshihara, Takeo and Tsujii, Yoshiki and Takehara, Tetsuo},
title = {Outcomes of additional chemotherapy for esophageal squamous cell carcinoma following non-curative endoscopic submucosal dissection},
journal = {International Journal of Clinical Oncology},
year = {2025},
doi = {10.1007/s10147-025-02893-0}
}
EUVIMED